Komal Plouffe
A5069304786- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Molecular Biology Techniques and Applications
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- Health Systems, Economic Evaluations, Quality of Life
- PARP inhibition in cancer therapy
Michigan Medicine
2018-2024
Michigan Center for Translational Pathology
2019-2024
University of Michigan
2018-2023
Ann Arbor Center for Independent Living
2019-2020
BACKGROUND. Commercial gene expression assays are guiding clinical decision making in patients with prostate cancer, particularly when considering active surveillance. Given heterogeneity and multifocality of primary such should ideally be robust to the coexistence unsampled higher grade disease elsewhere order have utility. Herein, we comprehensively evaluated transcriptomic profiles multifocal cancer assess robustness clinically relevant multifocality.
Abstract Background Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond immunohistochemistry, microsatellite instability, tumor mutation burden (TMB) may improve benefit prediction. Methods Using treatment data genomic transcriptomic tissue profiling from an observational trial (NCT03061305), we developed Immunotherapy Response Score (IRS), a pan-tumor predictive model of PD-(L)1 benefit. IRS real-world progression free survival...
Abstract Localized prostate cancer is frequently composed of multiple spatially distinct tumors with significant inter- and intra-tumoral molecular heterogeneity. This genomic diversity gives rise to many competing clones that may drive the biological trajectory disease. Previous large-scale sequencing efforts have focused on evolutionary process in metastatic cancer, revealing a potential clonal progression castration resistance. However, origin synchronous lymph node (LN) metastases...
Abstract Background: Predictive biomarkers for multiple ADCs/tumor types (beyond 3+ HER2 IHC) are lacking. We previously reported the discovery of ADC TRS—an algorithm combining individual target expression, proliferation, and adhesion by RNAseq to predict clinical benefit across tumor types/targets—and association with OS after treatment (Abstract 3140, ASCO 2024). Here we evaluated final TRS biomarker (ADC-specific; tuned on >100 type/ADC RRs) a qRT-PCR based trial assay (CTA)...
PURPOSE Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility PCa prognosis. METHODS Discovery validation cohorts included patients who underwent before radical prostatectomy were found harbor both mpMRI-visible (Prostate Imaging Reporting Data...
Immunotherapy response score (IRS) integrates tumor mutation burden (TMB) and quantitative expression biomarkers to predict anti-PD-1/PD-L1 [PD-(L)1] monotherapy benefit. Here, we evaluated IRS in additional cohorts. Patients from an observational trial (NCT03061305) treated with anti-PD-(L)1 were included assigned IRS-High (-H) versus -Low (-L) groups. Associations real-world progression-free survival (rwPFS) overall (OS) determined by Cox proportional hazards (CPH) modeling. Those...
3140 Background: Several ADCs are FDA-approved for patients with advanced solid tumors; dozens more in trials. Predictive biomarkers lacking, ADC target expression alone performing poorly across ADCs/tumor types. We previously described the development of Treatment Response Scores (ADC-TRS)—a tissue-based multivariate gene-expression test combining individual proliferation and adhesion—with high correlation per-ADC/tumor type biomarker frequency (TRS-High) corresponding clinical trial ORRs 9...
<title>Abstract</title> Localized prostate cancer is composed of multiple spatially distinct tumors with significant inter- and intra-tumoral molecular heterogeneity. This genomic diversity gives rise to many competing subclones that may drive the biological trajectory disease. Previous large scale sequencing efforts have focused on evolutionary process metastatic cancer, revealing a potential clonal progression castration resistance. However, origin synchronous lymph node (LN) metastases in...
<p>Supplementary Figure S8. shows overlap weighting propensity score analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort</p>
<p>Supplementary Data S1 shows the REMARK checklist for study</p>
<p>Supplementary Figure S5 shows robustness of Immunotherapy Response Score to self-reported race</p>
<p>Supplementary Figure S7. shows covariate adjusted Kaplan-Meier analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort</p>
<p>Supplementary Figure S2 shows a diagram of the overall study</p>
<p>Supplementary Figure S6 shows three group Immunotherapy Response Score classification of the anti-PD-(L)1 monotherapy validation cohort</p>
<p>Supplementary Figure S7. shows covariate adjusted Kaplan-Meier analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort</p>